Withdrawal from chronic cocaine administration causes prolonged deficits in L-tryptophan-induced head-twitch response in mice

Life Sciences

Volumn 61, Issue 12, 1997, Pages 1147-1158

  Darmani, Nissar A ^a  

^a A T STILL UNIVERSITY   (United States)

Author keywords

Cocaine; Head twitch response; L tryptophan

Indexed keywords

COCAINE; TRYPTOPHAN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG TOXICITY; DRUG WITHDRAWAL; HEAD TWITCH; LONG TERM EXPOSURE; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; SEROTONINERGIC SYSTEM; STATISTICAL ANALYSIS;

ANALYSIS OF VARIANCE; ANIMALS; COCAINE; DRUG ADMINISTRATION SCHEDULE; MALE; MICE; MICE, INBRED ICR; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; OPIOID-RELATED DISORDERS; SEROTONIN; STEREOTYPED BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TRANYLCYPROMINE; TRYPTOPHAN;

ANIMALIA; RODENTIA;

EID: 0030882991     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00647-4     Document Type: Article

References (43)

1. M.C. RITZ, E.J. CONE and M.J. KUHAR, Life Sci. 46 635-645 (1990).
2. C.W. BRADBERRY, J.B. NOBILETTI, J.D. ELSWORTH, D. MURPHY, P. JATLOW and R.H. ROTH, J. Neurochem. 60 1429-1435 (1993).
3. P.A. BRODERICK, E.P. KORNAK, F. ENG and R. WECHLER, Pharmacol. Biochem. Behav. 46 715-722 (1993).
4. K.A. CUNNINGHAM and J.M. LAKOSKI, Neuropsychopharmacology 3 41-50 (1990).
5. M.H. BAUMANN, T.J. RALEY, J.S. PARTILLA and R.B. ROTHMAN, Synapse 14 40-50 (1993).
6. S.I. DWORKIN, C. CO and J.E. SMITH, Brain Res. 682 116-126 (1995).
7. M.F. EGAN, L. WING, R. LI, D.G. KIRCH and R.J. WYATT, Biol. Psychiat. 36 637-640 (1994).
8. M.P. GALLOWAY, Synapse 6 63-72 (1990).
9. L.H. PARSONS and J.B. JUSTICE, JR., J. Neurochem. 61 1611-1619 (1993).
10. L.H. PARSONS, G.F. KOOB and F. WEISS, J. Pharmacol. Exp. Therap. 274 1182-1191 (1995).
11. F. WEISS, L.H. PARSONS and A. MARKOU, The Neurobiology of Cocaine: Cellular and Molecular Mechanisms, R.P. Hammer, Jr. (Ed), 163-180, CRC Press, Boca Raton, Florida (1995).
12. M.S. KLEVEN, W.L. WOOLVERTON and L.S. SEIDEN, Brain Res. Bull. 21 233-237 (1988).
13. L.S. SEIDEN and M.S. KLEVEN, Nat. Inst. Drug Abuse Mong Ser. 88 276-289 (1988).
14. S.Y. YEH and E.B. DE SOUZA, Drug Alcohol Depen. 27 51-61 (1991).
15. M.H. BAUMANN, K.M. BECKETTS and R.B. ROTHMAN, Eur. J. Pharmacol. 282 87-93 (1995).
16. A.D. LEVY, Q. LI and L.D. VAN DE KAR, Neuropharmacology 33 335-342 (1994).
17. A.D. LEVY, P.A. RITTENHOUSE, Q. LI, A.M. BONADONNA, M.C. ALVAREZ SANZ, J. E. KERR, C.L. BETHA and L.D. VAN DE KAR, Brain Res. 580 6-11 (1992).
18. M.H. BAUMANN, A.M. BROCKINGTON and R.B. ROTHMAN, Biol. Psychiat. 34 576-577 (1993).
19. M.H. BAUMANN and R.B. ROTHMAN, Neuropharmacology 35 295-301 (1996).
20. A.D. LEVY, Q. LI, M.C. ALVAREZ SANZ, P.A. RITTENHOUSE, M.S. BROWNFIELD and L.D. VAN DE KAR, Eur. J. Pharmacol. 221 121-127 (1992).
21. N.A. DARMANI, Life Sci. 59 1109-1119 (1996).
22. N.A. DARMANI and S.L. REEVES, Pharmacol. Biochem. Behav. 55 387-396 (1996).
23. P. HARTVIG, J. TEDROFF, K.J. LINDER, P. BJURLING, C.-W. CHANG, H. TSUKADA, Y. WATANABE and B. LANSTRÖM, J. Neural Trans. 94 127-135 (1993).
24. S.E. GARTSIDE, P.J. COWEN and T. SHARP, Neuropharmacology 31 9-14 (1992).
25. W.D. ESSMAN, A. SINGH, I. LUCKI, Pharmacol. Biochem. Behav. 49 107-113 (1994).
26. D.J. HEAL, G.P. LUSCOMBE, K.F. MARTIN, Pharmacological Characterization of 5-HT Receptor subtypes Using Behavioral Models, C. A. Marsden and D.J. Heal (Eds), 56-99, Blackwell Scientific Pub., London (1992).
27. S. KNAPP and A.J. MANDEL, Science 177 1209-1211 (1972).
28. N.A. DARMANI, B.R. MARTIN and R.A. GLENNON, Pharmacol. Biochem. Behav. 41 519-527 (1992).
29. A.D. LEVY, M.H. BAUMANN and L.D. VAN DE KAR, Front. Neuroendocrinology 15 85-156 (1994).
30. K.A. CUNNINGHAM, The Neurobiology of Cocaine: Cellular and Molecular Mechanisms, R.P. Hammer, Jr. (Ed), 121-143, CRC Press, Boca Raton, Florida (1995).
31. K.A. CUNNINGHAM, J.M. PARIS, N.E. GOEDERS, Synapse 11 112-123 (1992).
32. J.I. JAVAID, S.K. SAHNI, S.C. PANDEY and J.M. DAVIS, Eur. J. Pharmacol. 238 425-429 (1993).
33. R.G. JOHNSON, D. FIORELLA and R.A. RABIN, Pharmacol. Biochem. Behav. 46 289-293 (1993).
34. J.L. NEISEWANDER, I. LUCKI and P. MCGONIGLE, Synapse 16 1-10 (1994).
35. R.L. SMITH, R.J. BARRET and E. SANDERS-BUSH, J. Pharmacol. Exp. Therap. 254 484-488 (1990).
36. J. AKIYOSHE, C. HOUGH and D.-M. CHUANG, Mol. Pharmacol. 43 349-355 (1993).
37. M.S. GROTWIEL and E. SANDERS-BUSH, J. Neurochem. 63 1255-1260 (1994).
38. B.L. ROTH, E.-P. PALVIMAKI, S. BERRY, N. KHAN, N. SACHS, A. ULCER and M.S. CHOUDHARY, J. Pharmacol. Exp. Therap. 275 1638-1646 (1995).
39. N.A. DARMANI, M.G. HADFIELD, W.H. CARTER and B.R. MARTIN, Psychopharmacology 102 37-40 (1990).
40. N.A. DARMANI, B.R. MARTIN, U. PANDEY and R.A. GLENNON, Pharmacol. Biochem. Behav. 38 353-357 (1991).
41. M.G. PALFREYMAN, C.J. SCHMIDT, S.M. SORENSON, M.W. DUDLEY, J.H. KEHEN, P. MOSER, M.W. GITTOS and A.A. CARR, Psychopharmacology 1112 (Suppl. 1) S60-S67 (1993).
42. L.H. PARSONS and J.B. JUSTICE, JR., Brain Res. 606 195-199 (1993).
43. G. YADID, K. PACAK, L.J. KOPIN and D.S. GOLDSTEIN, J. Pharmacol. Exp. Therap. 270 1158-1165 (1994).